These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 21713039)

  • 1. A new drug design targeting the adenosinergic system for Huntington's disease.
    Huang NK; Lin JH; Lin JT; Lin CI; Liu EM; Lin CJ; Chen WP; Shen YC; Chen HM; Chen JB; Lai HL; Yang CW; Chiang MC; Wu YS; Chang C; Chen JF; Fang JM; Lin YL; Chern Y
    PLoS One; 2011; 6(6):e20934. PubMed ID: 21713039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
    Kao YH; Lin MS; Chen CM; Wu YR; Chen HM; Lai HL; Chern Y; Lin CJ
    Hum Mol Genet; 2017 Feb; 26(3):467-478. PubMed ID: 28069792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
    Chiang MC; Chen HM; Lai HL; Chen HW; Chou SY; Chen CM; Tsai FJ; Chern Y
    Hum Mol Genet; 2009 Aug; 18(16):2929-42. PubMed ID: 19443488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of novel dual-action compounds targeting the adenosine A(2A) receptor and adenosine transporter for neuroprotection.
    Chen JB; Liu EM; Chern TR; Yang CW; Lin CI; Huang NK; Lin YL; Chern Y; Lin JH; Fang JM
    ChemMedChem; 2011 Aug; 6(8):1390-400. PubMed ID: 21692183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.
    Guitart X; Bonaventura J; Rea W; Orrú M; Cellai L; Dettori I; Pedata F; Brugarolas M; Cortés A; Casadó V; Chang CP; Narayanan M; Chern Y; Ferré S
    Neurobiol Dis; 2016 Dec; 96():47-53. PubMed ID: 27567601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model.
    Chou SY; Lee YC; Chen HM; Chiang MC; Lai HL; Chang HH; Wu YC; Sun CN; Chien CL; Lin YS; Wang SC; Tung YY; Chang C; Chern Y
    J Neurochem; 2005 Apr; 93(2):310-20. PubMed ID: 15816854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
    Li W; Silva HB; Real J; Wang YM; Rial D; Li P; Payen MP; Zhou Y; Muller CE; Tomé AR; Cunha RA; Chen JF
    Neurobiol Dis; 2015 Jul; 79():70-80. PubMed ID: 25892655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
    Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
    Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards a transgenic model of Huntington's disease in a non-human primate.
    Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
    Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues.
    Chiang MC; Lee YC; Huang CL; Chern Y
    J Biol Chem; 2005 Apr; 280(14):14331-40. PubMed ID: 15689617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrodia elata prevents huntingtin aggregations through activation of the adenosine A₂A receptor and ubiquitin proteasome system.
    Huang CL; Yang JM; Wang KC; Lee YC; Lin YL; Yang YC; Huang NK
    J Ethnopharmacol; 2011 Oct; 138(1):162-8. PubMed ID: 21924340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the equilibrative nucleoside transporter ENT1 in Huntington disease.
    Guitart X; Chern Y; Ferré S
    Oncotarget; 2017 Feb; 8(8):12550-12551. PubMed ID: 28179589
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidating the role of the A2A adenosine receptor in neurodegeneration using neurons derived from Huntington's disease iPSCs.
    Chiu FL; Lin JT; Chuang CY; Chien T; Chen CM; Chen KH; Hsiao HY; Lin YS; Chern Y; Kuo HC
    Hum Mol Genet; 2015 Nov; 24(21):6066-79. PubMed ID: 26264576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.
    Dai Y; Dudek NL; Li Q; Fowler SC; Muma NA
    J Neurosci; 2009 Sep; 29(37):11550-9. PubMed ID: 19759302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of equilibrative nucleoside transporter 2 disturbs energy metabolism and exacerbates disease progression in an experimental model of Huntington's disease.
    Chen CY; Chou FY; Chang YG; Ho CJ; Wu KC; Hsu CL; Chern Y; Lin CJ
    Neurobiol Dis; 2023 Feb; 177():106004. PubMed ID: 36669543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
    Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
    Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperactivation of D1 and A2A receptors contributes to cognitive dysfunction in Huntington's disease.
    Tyebji S; Saavedra A; Canas PM; Pliassova A; Delgado-García JM; Alberch J; Cunha RA; Gruart A; Pérez-Navarro E
    Neurobiol Dis; 2015 Feb; 74():41-57. PubMed ID: 25449908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.